Aptose Presents New Preclinical Data for CG-806 at the 24th Congress of the European Hematology Association

Home/Client News/Aptose Presents New Preclinical Data for CG-806 at the 24th Congress of the European Hematology Association

Aptose Presents New Preclinical Data for CG-806 at the 24th Congress of the European Hematology Association

SAN DIEGO and TORONTO, June 14, 2019 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that new preclinical data for CG-806, its oral, first-in-class pan-FLT3/pan-BTK inhibitor, is being presented in a poster presentation today at the 24th Congress of the European Hematology Association in Amsterdam, the Netherlands.

By | 2019-06-14T14:19:01+00:00 June 14th, 2019|Client News|Comments Off on Aptose Presents New Preclinical Data for CG-806 at the 24th Congress of the European Hematology Association